Skip to main content

Search Results

Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas are highly aggressive blood cancer that have very poor survival rate, highlighting the need for new therapies to improve patient survival. We aim to improve our understanding of the characteristics of the individual cancer cells and their interaction with surrounding cells in the tumor environment with the goal of identifying new drugs that we can validate in preclinical models and move into more efficient treatments for lymphoma patients.

T-Cell Leukemia Lymphoma Foundation

To provide education and support to patients and to encourage research into these rare cancers

  • Provides disease, treatment and clinical trial information for the T-cell leukemias and lymphomas
  • Organizes free educational forums
  • Offers physician referrals, e-newsletter and links to helpful resources
  • Supports scientific research on the T-cell leukemias and lymphomas.

Patients, caregivers, healthcare professionals, researchers

Website or 206-661-2253 http://www.tcllfoundation.org/

Lymphoma Research Foundation (LRF)

To realize the promise of science to eradicate lymphoma and serve the community touched by this disease.

  • Provides Lymphoma Helpline and Clinical Trials Information Service
  • Provides educational materials, conferences, webcasts
  • Offers limited financial assistance to patients in active treatment
  • Lymphoma Support Network is a one-to-one peer support program that matches lymphoma patients or caregivers with volunteers who have had similar lymphoma-related experiences
  • Funds biomedical research focused on the origins, treatment and identification of a cure for lymphoma
  • Raises public awareness of the disease.

Patients with lymphoma and their families, caregivers, health professionals

800-500-9976 https://lymphoma.org/
International Resources
International Resources

Why: A Memoir of Love and Lymphoma

Why: A Memoir of Love and Lymphoma by John Melithoniotes
NFB Publishing, 2023, 278 Pages, Paperback or Kindle
ISBN: 9781953610485

There is no test of a couple’s bonds like the revelation that one of them has a life-threatening disease. One of them, a husband, wife, or partner, will become a patient who may need care from the other almost constantly. This is the story of John and Marilyn, whose love of nearly forty years encounters a diagnosis of Marilyn’s Non-Hodgkin’s lymphoma. John’s memoir describes the complexities of how they navigated their way through a large urban cancer hospital, their daily attempts to manage the side effects of chemotherapy, and their emotional struggle to cope with a worsening crisis. He revisits key scenes from their lives in the hope of understanding their actions and the surprises in store for both of them.

For more information click here

Suggested Reading-Why: A Memoir of Love and Lymphoma
Audience
Adults
Subject
Caregiving Decision Making Grief Inspiration Living with Cancer/Survivorship Side Effects Treatments

Suggested Reading - Living with Lymphoma

Living with Lymphoma By Elizabeth M. Adler, Ph.D.
The John Hopkins University Press, 2nd Edition, 2016, 480 pages
ISBN: 9781421418100

A comprehensive resource for coping with medical, emotional and practical challenges. The author, who is a lymphoma survivor, thoroughly explains the disease, describing the many different kinds of Hodgkin and non-Hodgkin lymphomas, the wide range of symptoms and the various treatment options available.The new edition includes the latest information on lymphoma diagnosis, treatment, and incidence and describes the most recent update to the WHO system of lymphoma classification and staging. Adler discusses new targeted therapies like ibrutinib and idelalisib and describes how other treatments, including radiation therapy and stem cell transplants, have been modified while others have been discontinued. 

Living with Lymphoma
Audience
Adults

A Brave Kid’s Guide to Lymphoma

A Brave Kid’s Guide to Lymphoma by Nina Gonzalez, MD
Hello Brave Co, 2024, 49 Pages, Paperback
ISBN: 979-8990710511

Charlie is a curious kid facing a big challenge: lymphoma. With so many questions swirling in his mind, Charlie finds a friend in Cobi, the super smart Brave Buddy who helps kids understand their medical diagnoses. Together, they set off on a journey of understanding, and Charlie realizes just how Brave he is.

A Brave Kid's Guide to Lymphoma is designed to help children understand their lymphoma diagnosis. Created by Dr. Nina Gonzalez and the Hello Brave team, this book breaks down complex medical information into simple, clear language and illustrations. Through an engaging conversation between Cobi and Charlie, this book helps to dispel common misconceptions and provides comfort through a shared understanding of this challenging diagnosis. At the end of the book, you'll find a glossary of easy-to-understand terms, guides for adults on how to talk about tough diagnoses like lymphoma with kids, questions to ask your care team, and a Brave Kid Certificate to honor your child's bravery and strength. This book is a supportive tool for both patients and families dealing with lymphoma.


For more information click here

Suggested Reading - A Brave Kid’s Guide to Lymphoma
Audience
Teens & Children

Hodgkin Lymphoma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

  • Healthy Bone Marrow
  • Normal Blood Cell Production
  • Proliferation of Cells and the Crowding Out of Normal Cells
  • Signs and Symptoms
 

Central Nervous System (CNS) Lymphoma

General Information

Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The cancer can also involve the spinal fluid that bathes the spinal cord and brain. This is called leptomeningeal lymphoma. Both primary and secondary CNS lymphomas are rare diseases.

JAK/STAT inhibition as a therapeutic strategy in T-cell lymphoma

Given the high rate of JAK/STAT pathway dysregulation in T-cell lymphomas, we aim to develop new personalized therapies with JAK inhibitors for T-cell lymphoma. Our recent study with ruxolitinib (a JAK inhibitor) showed that activation of a parallel oncogenic pathway, PI3-kinase, predicts for poor response to ruxolitinib in T-cell lymphoma. Building upon this observation, we are assessing whether dual inhibition of JAK and PI3-Kinase will lead to higher efficacy in T-cell lymphoma.

Bispecific antibody-based frontline therapy for follicular lymphoma

We are conducting a clinical trial testing a novel form of immunotherapy, called a bispecific antibody, as part of initial treatment for patients with follicular lymphoma. The goal of the trial is two-fold: 1) to establish a highly effective, chemotherapy-free treatment option for patients with follicular lymphoma, and 2) to establish predictors of response and toxicity that can guide treatment decisions for future patients with follicular lymphoma.

Towards Risk-Adapted Therapeutic Strategies in CNS Lymphoma

This project will significantly advance the treatment and prevention of CNS lymphomas in two key areas. One, we will further develop and validate candidate genomic biomarkers that identify high risk disease and that are useful in risk stratification in future clinical investigations in primary CNS lymphoma.

Brentuximab vedotin

Brentuximab vedotin is FDA approved for the treatment of:

Overcoming ibrutinib resistance in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive blood cancer which affects about 3,000 individuals in the United States annually. Despite advances of novel therapies in blood cancers, MCL remains incurable, and patients ultimately succumb to disease. We seek to evaluate longitudinal samples from patients with MCL treated with novel therapies to understand the mechanisms of drug resistance. We identify novel targets, with a particular focus on protein turnover pathways, to overcome drug resistance and improve survival of patients with MCL.

Lisocabtagene maraleucel

Lisocabtagene maraleucel is indicated for the treatment of

Epcoritamab-bysp

Epcoritamab-bysp is indicated for the treatment of 

  • Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma 
    • Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy
  • Follicular Lymphoma 
    • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy 

Axicabtagene ciloleucel

Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

Doctor in white lab coat looking at tablet with patient

What Is Blood Cancer?

Reviewed by Gwen Nichols, MD, EVP and Chief Medical Officer at The Leukemia & Lymphoma Society